SELLAS Life Sciences Gr Q2 EPS $(0.13) Beats $(0.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
SELLAS Life Sciences Group (NASDAQ:SLS) reported a Q2 EPS of $(0.13), beating the analyst consensus estimate of $(0.17) by 23.53%. This represents a 58.06% improvement over the $(0.31) loss per share from the same period last year.
August 13, 2024 | 8:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SELLAS Life Sciences Group reported a Q2 EPS of $(0.13), beating the analyst consensus estimate of $(0.17) by 23.53%. This is a significant improvement over the $(0.31) loss per share from the same period last year.
The better-than-expected EPS and significant year-over-year improvement are likely to positively impact the stock price in the short term as it indicates better financial performance and potential investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100